10-Q: Cabaletta Bio Reports Q3 2025 Results, Advances Autoimmune Cell Therapies

Cabaletta Bio reported increased net losses and significant R&D expenses in Q3 2025, while advancing multiple rese-cel clinical trials and securing additional financing to extend its cash runway into H2 2026.

Summary

• Net loss for the three months ended September 30, 2025, was $44.866 million, compared to $30.629 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $125.937 million, compared to $83.278 million for the same period in 2024.
• Research and development expenses increased to $39.824 million for Q3 2025 from $26.290 million in Q3 2024, primarily due to expanded cell processing capabilities, increased patient enrollment, and commercial readiness activities.
• General and administrative expenses remained comparable at $6.764 million for Q3 2025 versus $6.756 million for Q3 2024.
• Cash, cash equivalents, and investments totaled $159.931 million as of September 30, 2025.
• The company expects its current cash, cash equivalents, and investments to fund operations into the second half of 2026.
• Substantial doubt exists about the company's ability to continue as a going concern beyond the second half of 2026 without additional funding.
• The June 2025 financing raised aggregate net proceeds of $93.558 million through the issuance of common stock, warrants, and pre-funded warrants.
• Clinical trials for rese-cel (RESET-Myositis, RESET-SLE, RESET-SSc, RESET-MG, RESET-PV, RESET-MS) are actively enrolling patients or have completed enrollment for certain cohorts, with preliminary positive data reported for several programs.
• The company is initiating a DM/ASyS registrational cohort within the RESET-Myositis trial in Q4 2025, with BLA submission expected in 2027.
• Rese-cel has received multiple regulatory designations, including Fast Track (DM, SLE/LN, SSc, MS), Orphan Drug (myositis, SSc), Rare Pediatric Disease (juvenile dermatomyositis), and Regenerative Medicine Advanced Therapy (RMAT) for myositis.

Sentiment

Score: 4

Explanation: While the company demonstrates strong clinical progress, regulatory designations, and successful interim financing, the significant increase in net losses and the explicit 'going concern' warning highlight substantial financial challenges and a high burn rate. The need for continuous capital raises and the inherent risks of clinical-stage biotech temper the positive developments, indicating a precarious financial position despite scientific advancements.

Positives

• Advancement of multiple rese-cel clinical trials (RESET-Myositis, RESET-SLE, RESET-SSc, RESET-MG, RESET-PV, RESET-MS) with active enrollment or completed cohorts.
• Initiation of a DM/ASyS registrational cohort within the RESET-Myositis trial in Q4 2025, with BLA submission expected in 2027, following FDA alignment on trial design.
• Positive preliminary clinical data from RESET-MG, showing rese-cel was generally well tolerated, with significant improvements in MG-ADL and Minimal Symptom Expression in evaluable patients, who remain off immunomodulatory medication.
• Positive preliminary clinical data from RESET-PV, demonstrating similar CAR T cell expansion and contraction kinetics, substantial B cell depletion, rapid autoantibody reduction, and low BAFF increase, with all three patients remaining off immunomodulators.
• Positive preliminary clinical data from RESET-SSc, with all four patients with at least three months of follow-up achieving an rCRISS-25 response off immunomodulators and steroids.
• Positive preliminary clinical data from RESET-SLE, showing three of four patients achieving DORIS, one achieving a complete renal response, all nine patients off immunomodulators, and significant reductions in SLEDAI-2K and anti-dsDNA antibodies.
• Multiple regulatory designations for rese-cel, including Fast Track (dermatomyositis, SLE/LN, systemic sclerosis, multiple sclerosis), Orphan Drug (myositis, systemic sclerosis), Rare Pediatric Disease (juvenile dermatomyositis), and Regenerative Medicine Advanced Therapy (RMAT) for myositis.
• Successful June 2025 financing raising $93.558 million in net proceeds, extending the cash runway into the second half of 2026.
• Expanded manufacturing partnerships with Minaris and Lonza for global clinical development and commercial readiness activities for rese-cel.
• Successful conclusion of the Cellares Cell Shuttle Technology Adoption Program, facilitating potential integration of automated manufacturing for rese-cel.

Negatives

• Net loss significantly increased to $44.866 million for Q3 2025 from $30.629 million in Q3 2024, and to $125.937 million for the nine months ended September 30, 2025, from $83.278 million in the prior year period.
• The company has identified conditions that raise substantial doubt about its ability to continue as a going concern beyond the second half of 2026 without securing additional funding.
• Cash and cash equivalents decreased from $163.962 million at December 31, 2024, to $60.206 million at September 30, 2025, despite a significant capital raise.
• Interest income decreased by $0.6 million for Q3 2025 and $3.4 million for the nine months ended September 30, 2025, primarily due to lower cash, cash equivalents, and investment balances.
• One Grade 3 immune effector cell-associated neurotoxicity syndrome (ICANS) event was observed in the RESET-SSc trial (previously reported in March 2025).
• One Grade 4 ICANS event was observed in the RESET-SLE trial (previously reported in August 2024).
• In a subset of ASyS and IMNM patients, rese-cel did not lead to antibody clearance, suggesting CD19 long-lived plasma cells may be a clinically meaningful source for pathogenic autoantibodies.
• Patient 1 in the RESET-PV trial experienced transient fever (grade 1 cytokine release syndrome), and Patient 2 required a course of steroids for a disease flare post-infusion.

Risks

• The company is a clinical-stage company with a limited operating history, has incurred significant losses since inception, and anticipates continued substantial losses.
• High dependency on relationships with University of Pennsylvania (Penn), Minaris Advanced Therapies, LLC (Minaris), and Lonza Houston Inc. (Lonza) for manufacturing needs; capacity reductions or delays could adversely impact trials.
• Reliance on intellectual property licensed from Penn and Nanjing IASO Biotherapeutics Co., Ltd. (IASO); termination of these license agreements would result in loss of significant rights.
• Inability to obtain and maintain sufficient intellectual property protection for current and future product candidates.
• Need to raise substantial additional funding to complete development of product candidates or generate revenue from product sales.
• Limited operating history makes it difficult to evaluate business success and future viability.
• Inability to successfully develop current programs into a portfolio of product candidates, or significant delays in doing so.
• Difficulties enrolling patients in RESET clinical trials for rese-cel or future clinical trials could delay or adversely affect clinical development.
• Inability to advance product candidates through clinical development, obtain regulatory approval, and commercialize them, or significant delays in doing so.
• Results of earlier studies may not be predictive of future study or trial results; potential failure to establish an adequate safety and efficacy profile.
• Identification of serious adverse events, undesirable side effects, or unexpected characteristics during development may delay, abandon, or limit further clinical development.
• Manufacturing and administering product candidates is complex, with potential difficulties in technology transfer to contract manufacturing organizations.
• Substantial competition from other biotechnology and pharmaceutical companies.
• Establishing own manufacturing facility and infrastructure will be costly, time-consuming, and may not be successful.
• Future success depends on ability to retain key employees, consultants, and advisors, and to attract, retain, and motivate other qualified personnel.
• Substantial doubt about the company's ability to continue as a going concern if additional funding is not secured beyond the second half of 2026.
• Cellular therapies represent a novel approach; negative perception or increased regulatory scrutiny (e.g., FDA investigation into T cell malignancies for CAR T therapies) could adversely affect business or approvals.
• Patients receiving T cell-based immunotherapies may experience serious adverse events, including ICANS, CRS, and off-target killing of cells.
• Preconditioning regimens may increase the risk of adverse side effects and impact the ability to accurately assess product candidate efficacy.
• Market opportunities for product candidates may be limited to specific patient populations and be small.
• Market acceptance of product candidates may be inhibited by price competition or physician reluctance to switch from existing treatments.
• Failure to identify additional product candidates or focus on programs that ultimately prove unsuccessful.
• Business disruptions, including due to natural disasters, global conflicts, or political unrest, could seriously impact operations, research, and trials.
• Reliance on third parties to conduct clinical trials; failure to successfully carry out contractual duties or meet expected deadlines.
• Reliance on third parties to manufacture clinical product supplies; difficulties could delay or stop supply or prevent commercially viable cost structure.
• Complexity and variability of viral vector manufacturing, with a limited number of manufacturers.
• Operating own manufacturing facility would require significant resources and may fail to be successful.
• The regulatory approval process is lengthy and time-consuming, with potential for significant delays.
• Uncertain regulatory landscape for novel cell therapies; changes in regulatory requirements could result in delays or discontinuation of development.
• Even if regulatory approval is received, ongoing regulatory obligations and continued review may result in significant additional expense and potential penalties for non-compliance.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• Employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities.
• Healthcare coverage and reimbursement may be limited or unavailable, making it difficult to sell product candidates profitably.
• Healthcare legislative measures aimed at reducing healthcare costs may adversely affect business and results of operations.
• Relationships with customers, healthcare providers, physicians, and third-party payors are subject to federal and state healthcare fraud and abuse laws, false claims laws, and privacy laws.
• Data collection is governed by restrictive regulations (e.g., GDPR, CCPA, CPRA); non-compliance could lead to fines or reputational harm.
• Security breaches or unauthorized access to confidential and/or proprietary information could harm reputation and incur significant liabilities.
• Principal stockholders and management own a large percentage of stock, potentially exerting significant control over corporate matters.
• Failure to establish and maintain proper and effective internal control over financial reporting could harm operating results.
• The dual class structure of common stock may limit stockholders' ability to influence corporate matters.
• Sales of a substantial number of shares by existing stockholders could cause the stock price to fall.
• Outstanding common stock warrants may not be exercised, limiting additional funds.
• Pre-funded warrants will not provide meaningful additional funds upon exercise, leading to dilution.
• Anti-takeover provisions under charter documents and Delaware law could delay or prevent a change of control.
• Changes in tax laws could adversely affect business and financial condition.
• Ability to utilize net operating losses and certain other tax attributes may be subject to limitations.
• Adverse developments affecting the financial services industry could adversely affect business operations.
• Public health crises could seriously harm research, development, and potential future commercialization efforts.
• The price of common stock may be volatile, leading to potential loss of investment.
• Business is affected by macroeconomic conditions, including rising inflation, interest rates, and supply chain constraints.
• No intention to pay dividends on common stock.
• Smaller reporting company status may make common stock less attractive to investors.
• Raising additional capital may cause dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies.

Future Outlook

The company expects to incur significant losses for the foreseeable future, with these losses increasing substantially as it continues research and development efforts, conducts clinical trials, invests in manufacturing, and pursues commercialization. Current cash, cash equivalents, and investments are projected to fund operations into the second half of 2026. The company anticipates aligning with the FDA on registrational cohort designs for SLE/LN and SSc in Q4 2025, and for MG in H1 2026. Enrollment in the DM/ASyS registrational cohort is on track for Q4 2025, with a Biologics License Application (BLA) submission expected in 2027. The company is also expanding its rese-cel program into lupus without preconditioning, with initial clinical data anticipated in 2026. Significant additional financing will be required to complete clinical trials and commercialization, which the company intends to raise through various capital sources.

Management Comments

• "We are a clinical-stage biotechnology company focused on the discovery and development of innovative engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases."
• "We believe our CABA platform has the potential to safely enable complete and durable responses for a broad range of autoimmune diseases and that it has potential applicability across dozens of autoimmune diseases that we have identified, evaluated and prioritized."
• "We remain on track to initiate enrollment in the registrational DM/ASyS cohort in the fourth quarter of 2025 with expected BLA submission in 2027."
• "Based on our current operating plan, we believe there is substantial doubt about our ability to continue as a going concern for at least twelve months following the filing of this Quarterly Report on Form 10-Q, and we will need to obtain additional funding."

Industry Context

The company operates in the highly innovative and rapidly evolving field of engineered T cell therapies for autoimmune diseases, a novel approach with no currently licensed cellular immunotherapies for these indications in the U.S. or EU. This creates both significant opportunity for transformative treatments and substantial regulatory and development challenges. The industry is characterized by complex manufacturing processes, high R&D costs, and increasing regulatory scrutiny, as evidenced by the FDA's investigation into T cell malignancies for CAR T therapies. Cabaletta Bio's strategy of leveraging academic partnerships (Penn, CHOP) and contract development and manufacturing organizations (CDMOs like Minaris, Lonza, Oxford Biomedica) for clinical supply and commercial readiness aligns with common biotech industry practices. The exploration of automated manufacturing platforms like Cellares Cell Shuttle reflects a broader industry trend towards optimizing scalability and cost-efficiency for cell therapies.

Comparison to Industry Standards

• The planned size of 14 patients for the DM/ASyS registrational cohort is based on assumed treatment effect and an estimated background rate from an external myositis patient registry, aligned with FDA guidance, with statistical positivity requiring 5/14 patients at a 10% background rate or 8/14 at a 25% background rate.
• The FDA supported pooling rese-cel safety data from across the entire RESET clinical trial program to supplement myositis-specific safety data for the BLA submission, aligning on a required safety database of approximately 100 autoimmune disease patients treated with the same single weight-based dose.
• PDAI activity scores, which formed the basis for recent regulatory approvals in Pemphigus Vulgaris (PV), were reported to be consistent with PDAI activity scores in the late-breaking clinical trial session for RESET-PV.
• While rituximab is the first drug approved in over 60 years for PV, the company acknowledges other biopharmaceutical companies are developing therapies for MuSK MG, SLE, myositis, SSc, gMG, and MS, indicating a competitive landscape.
• The company notes that competitors developing CAR T cell therapies have experienced difficulties reliably producing engineered T cell therapies in a commercial setting, highlighting a common industry challenge.

Corporate Governance

Legal Proceedings

• As of September 30, 2025, the company is not involved in any material litigation or legal proceedings that it would expect to have a material adverse impact on its financial position, results of operations, or cash flows.
• A securities class action lawsuit filed in February 2022 against certain officers and directors was voluntarily dismissed by the plaintiff in October 2022.

Related Party Transactions

• Amended and Restated License Agreement with the Trustees of the University of Pennsylvania (Penn) and Children's Hospital of Philadelphia (CHOP) for intellectual property rights.
• Master Translational Research Services Agreements with Penn for research, development, and manufacturing services.
• Exclusive License Agreement with Nanjing IASO Biotherapeutics Co., Ltd. (IASO) for a novel clinical-stage anti-CD19 binder.
• Option and License Agreement with Autolus Holdings (UK) Limited (Autolus) for access to RQR8 technology.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings and a decline in stock price due to increased losses and the 'going concern' warning, but also potential for appreciation if clinical trials succeed.
• Employees benefit from the stock option repricing, which aims to retain talent, and potential increased headcount, but face uncertainty related to the company's long-term financial viability.
• Future patients could benefit from novel, potentially curative T cell therapies for autoimmune diseases, but must weigh the risks of side effects and trial delays.
• Suppliers and partners (Penn, Minaris, Lonza, Oxford, Cellares) have ongoing and expanded agreements, indicating continued business, but are exposed to risks of contract termination or non-performance.
• Creditors face increased risk due to the company's accumulated deficit and the explicit 'going concern' doubt, which may affect future lending terms.

Next Steps

• Initiate enrollment in the registrational DM/ASyS cohort within the RESET-Myositis trial in the fourth quarter of 2025.
• Submit the registry protocol and statistical analysis plan for the DM/ASyS registrational cohort to the FDA this year.
• Anticipate aligning with the FDA on the registrational cohort design for studies in SLE/LN in the fourth quarter of 2025.
• Anticipate aligning with the FDA on the registrational cohort design for studies in SSc in the fourth quarter of 2025.
• Anticipate aligning with the FDA on the registrational cohort design for studies in MG in the first half of 2026.
• Anticipate initial clinical data from the new dose-escalation cohort in the RESET-SLE trial (without preconditioning) in 2026.
• Expect Biologics License Application (BLA) submission for the DM/ASyS registrational cohort in 2027.
• Continue to invest in research and development activities, including manufacturing.
• Seek additional financing through equity offerings, debt financings, government funding arrangements, strategic alliances, or other sources to fund future operations.
• Expand the employee base and add managerial, operational, sales, research and development, marketing, financial, and other personnel.
• Further develop the product candidate platform and discover additional product candidates.
• Maintain, expand, and protect the intellectual property portfolio.
• Establish a commercial manufacturing source and secure supply chain capacity.
• Seek marketing approvals for any product candidates that successfully complete clinical trials.
• Establish a sales, marketing, and distribution infrastructure to support commercialization efforts.
• Add operational, financial, and management information systems and personnel.

Key Dates

Recommendation

While Cabaletta Bio has demonstrated promising clinical progress with its rese-cel programs, securing multiple regulatory designations and reporting positive preliminary data, the significant increase in net losses and the explicit 'substantial doubt about our ability to continue as a going concern' are major red flags. The company's high cash burn rate necessitates continuous capital raises, which will likely lead to further shareholder dilution. The stock option repricing also suggests past underperformance. A 'hold' recommendation allows investors to monitor the company's ability to successfully secure the necessary additional funding and advance its registrational trials, as the long-term viability and potential for commercial success are highly contingent on these critical financial and operational milestones.

Keywords

Cell therapy, Autoimmune disease, CAR T, CAAR T, rese-cel, CABA platform, Clinical trials, Biotechnology, Systemic lupus erythematosus, Myositis, Systemic sclerosis, Myasthenia gravis, Pemphigus vulgaris, Multiple sclerosis, FDA, Regulatory approval, Manufacturing, Financing, Orphan Drug, Fast Track, RMAT, Going concern